1. Pink Sheet
  2. >>Legislation

Shanghai Seizes Cell Samples As China Tightens Biosecurity Enforcement

First Action Since 15 April Law Enactment

 
• By Brian Yang

Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized. 

China tightens biosecurity law enforcement
CHINA TIGHTENS BIOSECURITY LAW ENFORCEMENT IN LATEST ACTION • Source: Alamy

Shanghai Customs authorities announced on 9 May they had intercepted over 200 human cell samples imported from overseas that had been disguised as other liquid cultures.

The importer, an unnamed biotech firm in Shanghai, was found to “hidden 247 reagents of human cells” and to “have repeatedly used a similar method to smuggle human cell samples,” an official notice stated

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.